Ozempic Vision Loss Lawsuit
(NAION / Sudden Blindness)
New federal litigation alleging GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Mounjaro caused non-arteritic anterior ischemic optic neuropathy (NAION) — sudden, typically irreversible vision loss. Created December 2025 after Harvard study found 4-7x higher risk.
Key Takeaways
- MDL created December 15, 2025 — one of the newest federal MDLs
- Harvard/JAMA study found 4.28x higher risk for diabetics, 7.64x higher for weight loss patients
- June 2025: European Medicines Agency confirmed NAION as "very rare" side effect
- Same judge as MDL-3094 (GI claims) — Judge Karen S. Marston
- Vision loss is typically sudden, painless, and permanent
May 2026 Updates Latest
86 cases now pending (86 total filed), up from 73 in April — growth continues as more NAION patients file claims in the Eastern District of Pennsylvania. Science Day is now less than one month out, set for June 2, 2026, when Judge Karen Marston will hear non-adversarial scientific presentations from both sides on the link between semaglutide-class drugs and non-arteritic anterior ischemic optic neuropathy. The hearing is widely viewed as the gating event before any case-management or bellwether-selection schedule is set.
U.S. FDA has still NOT added a NAION warning to GLP-1 drug labels — a regulatory gap that remains central to plaintiffs' failure-to-warn theory. Plaintiffs continue to rely on the JAMA Ophthalmology study showing semaglutide patients experienced NAION at over 7x the rate of patients on other medications. Co-Lead Counsel Parvin Aminolroaya (Seeger Weiss) continues to lead the plaintiffs' executive committee, with discovery and bellwether selection expected to follow Science Day.
Case Growth Tracking
Newly formed MDL tracking case filings since creation in December 2025.
Source: JPML MDL Statistics Reports
Key Facts (May 2026)
| Pending Actions | 86 cases (newly formed MDL) |
| MDL Created | December 15, 2025 |
| Key Defendants | Novo Nordisk Inc./A/S, Eli Lilly and Company |
| Presiding Judge | Hon. Karen S. Marston (E.D. Pennsylvania) |
| Alleged Injury | NAION — sudden, permanent vision loss |
| Key Study | Harvard/Mass Eye & Ear (JAMA Ophthalmol. July 2024) |
| EMA Label Status | June 2025: NAION added as "very rare" side effect |
| FDA Label Status | No NAION warning (as of May 2026) |
| Can You Still File? | Yes, lawsuits are actively being filed |
Harvard JAMA Ophthalmology Study (July 2024)
Researchers at Massachusetts Eye and Ear (Harvard Medical School) observed three NAION cases in one week — all in patients taking semaglutide. The subsequent study of 16,827 patients found significantly elevated risk:
Source: Hathaway JT, et al. JAMA Ophthalmol. 2024;142(8):732-739 (PMID: 38958939)
1 What Is NAION?
Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common cause of sudden optic nerve blindness in adults. It occurs when blood flow to the front of the optic nerve is disrupted, causing permanent damage — sometimes called a "stroke of the optic nerve."
How NAION Presents
- Sudden, painless vision loss — often discovered upon waking
- Usually affects one eye — can affect second eye in 15-25% of cases over 5 years
- Vision loss is typically permanent — no effective treatment exists
- Affects approximately 21,000 Americans annually
2 Why Two GLP-1 MDLs?
The JPML created a separate MDL for NAION claims rather than adding them to MDL-3094 (gastroparesis). Here's how they differ:
| Factor | MDL-3094 (GI) | MDL-3163 (Vision) |
|---|---|---|
| Primary Injuries | Gastroparesis, ileus, intestinal obstruction | NAION, sudden vision loss, blindness |
| Case Count | ~3,300+ cases | ~54 cases |
| Established | February 2024 | December 2025 |
| Expert Type | Gastroenterology | Ophthalmology, Neuro-ophthalmology |
| FDA Warning | Oct 2025: Gastroparesis warning added | No U.S. warning |
3 Regulatory Status: EMA vs FDA
European Medicines Agency (June 2025)
The EMA's Pharmacovigilance Committee (PRAC) concluded that NAION is a "very rare" side effect of semaglutide. They recommended adding NAION to European drug labels and advising patients to stop the medication if NAION is confirmed.
U.S. FDA (As of March 2026)
NAION is NOT included in U.S. drug labels for Ozempic, Wegovy, or Rybelsus. The FDA is reportedly evaluating whether action is required. This regulatory gap is central to plaintiffs' failure-to-warn claims.
4 Scientific Evidence
Key Studies
Proposed Mechanisms (Under Investigation)
- • Rapid metabolic changes affecting optic nerve perfusion
- • Enhanced sympathetic activity impacting vascular tone
- • Pre-existing microvascular damage in diabetic patients
Dr. Joseph Rizzo at Harvard has received NIH funding to study GLP-1 receptors in optic nerve tissue.
5 Do You Qualify?
Eligibility for NAION Claims
- Took a GLP-1 drug — Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or similar
- Diagnosed with NAION — Confirmed by ophthalmologist or neuro-ophthalmologist
- Sudden vision loss — Typically painless, often discovered upon waking
- Medical documentation — Prescription records, eye exam records, diagnosis confirmation
6 Frequently Asked Questions
Is NAION vision loss permanent?
Why hasn't the FDA added a warning?
What if I have both GI and vision problems?
Are Mounjaro and Zepbound included?
When will there be trials?
7 Key Timeline
Research showing 4-7x higher NAION risk sparks litigation
European regulators begin investigating NAION-semaglutide link
NAION added to European drug labels as "very rare" side effect
State-level consolidation of NAION and GI claims
Federal NAION cases consolidated before Judge Marston in E.D. Pennsylvania
Sources & References
8 official sources cited• JPML Transfer Order MDL-3163 (December 15, 2025)
• Hathaway JT, et al. "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide." JAMA Ophthalmol. 2024;142(8):732-739 (PMID: 38958939)
• Cai CX, et al. "Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy." JAMA Ophthalmol. 2025;143(4):304-314 (PMID: 39976940)
• European Medicines Agency — Wegovy Product Information (June 2025 PRAC decision)
• American Academy of Ophthalmology — "What Is Ischemic Optic Neuropathy?"
• FDA DailyMed — Ozempic Prescribing Information (October 2025)
• JPML MDL Statistics Report (March 2026)
• U.S. District Court, Eastern District of Pennsylvania — MDL-3163 docket
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.